Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

• Status: Terminated
• Trial end date: 2018-07-26
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase II, dose ranging, multicenter, randomized, double-blind, placebo-controlled study.

The aim of this study is to assess the safety of increasing doses of roscovitine administered orally for 4 cycles of 4 consecutive days (treatment "on") separated by a 3 days treatment free period (treatment "off") in adult CF subjects with Cystic Fibrosis carrying 2 Cystic Fibrosis causing mutations with at least one F508del-CFTR mutation and chronically infected with Pseudomonas aeruginosa.

This study involved 36 Cystic Fibrosis patients: 24 treated and 12 controls.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Brest
• Collaborators: Cyclacel Pharmaceuticals, Inc.; ManRos Therapeutics
• Treatments: Roscovitine

Criteria

Inclusion Criteria:

• Male or female aged over 18 years of age on the date of informed consent;

• Diagnosed CF patients. Confirmed diagnosis of CF (Rosenstein and Cutting, 1998);

• Patients carrying 2 Cystic Fibrosis causing mutations with at least one F508del-CFTR mutation, genotype to be confirmed at screening;

• Forced expiratory volume at 1 second (FEV1) 40%

• Chronic lung Pseudomonas aeruginosa infection according to the definition from the French Consensus Conference;

• Able to understand and comply with all protocol requirements, restrictions and instructions and likely to complete the study as planned (as judged by the investigator);

• Provide written informed consent prior to the performance of any study-related procedure;

Exclusion Criteria:

• Acute upper or lower respiratory infection, pulmonary exacerbation or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before V2;

• Recent patient reported history of:

• non recovered viral upper respiratory tract infection

• solid organ or hematological transplantation

• Burkholderia cepacia complex or Non Tuberculous Mycobacteria (NTM) respiratory tract infection;

• Undergone major surgery within 1 month prior to screening;

• Currently treated allergic broncho-pulmonary aspergillosis (ABPA);

• Diabetic patients whose blood glucose is poorly controlled as evidenced by HbA1C >8%;

• Hemoptysis more than 60 mL at any time within 4 weeks prior to first study drug administration (V2);

• History of any other comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject;

• Any other clinically significant conditions (not associated with the study indication) at Screening (V1) which might interfere with the assessment of this study;

• Any of the following abnormal laboratory values at screening:

• Hemoglobin <10 g/dL

• Abnormal liver function

• Serum K+ <3,5 mmol/L

• Abnormal renal function

• Any clinically significant laboratory abnormalities;

• Patients who have clinically significant impairment in cardiovascular function;

• Concomitant disease(s) that could prolong the QT interval;

• Patients with a history of alcohol or drug abuse in the past year;

• Patients with a history of noncompliance to medical regimens and patients or caregivers who are considered potentially unreliable;

• Use of one (or several) prohibited medications and/or food;

• Administration of any investigational drug within 30 days prior to Screening (V1) or 5 half-lives, whichever is longer;

• Use of systemic anti-pseudomonal antibiotics within 28 days prior to first study drug administration (V2). However use of inhaled anti-pseudomonal antibiotic treatment is allowed if initiated for more than 28 days;

• Use of loop diuretics within 7 days prior to first study drug administration (V2);

• Pregnant or nursing females.